Results 141 to 150 of about 19,166 (184)

The varieties of therapeutic experience: navigating treatment options for patients with PNH. [PDF]

Hematology Am Soc Hematol Educ Program
Bienz M, Patriquin CJ.
europepmc   +1 more source

Bioorthogonal tuning of nanosurface opsonisation <i>via</i> click coupling of a complement fusion protein inhibitor.

Chem Commun (Camb)
Jacques S, Gaikwad H, Pillatzke J, Moghimi SM, Simberg D.   +4 more
europepmc   +1 more source

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy. [PDF]

Hemasphere
Kulasekararaj A, de Fontbrune FS, Gaya A, Weitz I, Kuter DJ, Patel BJ, Araten DJ, Singh A, Jang JH, Kelly RJ, Di Bona E, Loschi M, Pullarkat V, Schubert J, Notaro R, Yenerel MN, Beckman J, Blin N, Murakhovskaya I, Panse J, Roman E, Röth A, Schrezenmeier H, Tantravahi S, de Latour RP, Mahajan N, Monaco L, Ding T, Lawniczek T, Ferber P, Dahlke M, Risitano AM.   +31 more
europepmc   +1 more source

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade. [PDF]

Cureus
Hamadah A, Eleraky T, Kumar D, Mohan D, Bibi A, Leal H, Alhadari A.   +6 more
europepmc   +1 more source

Ornithodoros moubata complement inhibitor (OmCI)—A novel and efficient C5 inhibitor in the pig

Molecular Immunology, 2010
Complement and CD14/TLR4 are two important upstream components of innate immunity. Inflammation induced by these danger sensors may be excessive and detrimental in conditions such as sepsis. Inhibition of complement or CD14/TLR4 differentially attenuate experimentally induced inflammation.
Barratt-Due, Andreas, Thorgersen, Ebbe B., Lindstad, Julie, Pharo, Anne, Nunn, Miles A., Mollnes, Tom E.   +5 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

A small-molecule inhibitor of C5 complement protein

Nature Chemical Biology, 2019
The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria.
Keith Jendza, Mitsunori Kato, Michael Salcius, Honnappa Srinivas, Andrea De Erkenez, Anh Nguyen, Doug McLaughlin, Celine Be, Christian Wiesmann, Jason Murphy, Philippe Bolduc, Muneto Mogi, Jose Duca, Abdel Namil, Michael Capparelli, Veronique Darsigny, Erik Meredith, Ritesh Tichkule, Luciana Ferrara, Jessica Heyder, Fang Liu, Patricia A. Horton, Michael J. Romanowski, Markus Schirle, Nello Mainolfi, Karen Anderson, Gregory A. Michaud   +26 more
openaire   +3 more sources

Development of an Automated Complement C5 Functional Assay for Personalized Monitoring of Patients on C5 Inhibitors

American Journal of Clinical Pathology, 2022
Abstract Background Humanized anti-C5 monoclonal antibody therapeutics has been heralded as a breakthrough treatment for Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome. Therapeutic drug monitoring is currently not widely available but assessing complement blockage maybe ...
Thomas Martins, Tanya Wilcox, Desirae Muhlestein, Marc Elgort, Julio Delgado, Vijayalakshmi Nandakumar   +5 more
openaire   +1 more source

Derivation of RNA aptamer inhibitors of human complement C5

Immunopharmacology, 1999
Specific aptamer inhibitors of the human complement C5 component were produced by the SELEX methodology of directed evolution of nucleic acid ligands. The SELEX procedure started with a pool of random-sequence, 2'F-pyrimidine-modified nuclease-stabilized RNA, and after twelve rounds of iterative C5 binding and nucleic acid amplification an evolved RNA ...
G, Biesecker, L, Dihel, K, Enney, R A, Bendele   +3 more
openaire   +2 more sources

Study of chondroitin sulfate E oligosaccharide as a promising complement C5 inhibitor for osteoarthritis alleviation

Materials Science and Engineering: C, 2021
Osteoarthritis (OA) is a degenerative joint disease which is highly prevalent worldwide. However, no therapy for blocking OA pathogenesis is available currently. In this study, chondroitin sulfate (CS) E oligosaccharides were prepared and we identified disaccharide as the functional unit showing the strongest anti-complement activity and screened out ...
Chen, Yu, Hengchang, Zang, Cui, Yang, Dong, Liang, Shuang, Quan, Danyang, Li, Yanni, Li, Qin, Dong, Fengshan, Wang, Lian, Li   +9 more
openaire   +2 more sources